We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
Read MoreHide Full Article
Key Takeaways
Shares of PFE fell after 2026 guidance projected $59.5B-$62.5B in revenue and adjusted EPS of $2.80-$2.90.
PFE expects COVID product sales to decline in 2026 as patent losses rise over $3B in 2027 and $6B in 2028.
PFE reaffirmed $7.2B in cost cuts by 2027, but said new launches won't drive a growth inflection until 2029.
Shares of Pfizer (PFE - Free Report) dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026, which fell short of investor expectations. The company is expected to have a soft financial performance over the next three years, owing to waning demand for COVID-19 products and a rising loss of exclusivity (LOE) across its portfolio.
Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, which includes $5 billion from the sales of its COVID-19 products. While this outlook is in line with the Zacks Consensus Estimate of $61.83 billion, it implies modest growth compared with the company’s revised 2025 revenue expectation of around $62 billion (previous guidance: $61-$64 billion).
The company also issued guidance for adjusted EPS for 2026, which stood at $2.80-$3.00. This guidance, however, fell short of the Zacks Consensus Estimate of $3.08 per share. Adjusted R&D expenses are expected to be in the range of $10.5 to $11.5 billion in 2026, while adjusted SI&A spending is targeted between $12.5 billion and $13.5 billion. The adjusted effective tax rate is expected to be approximately 15% in 2026.
During the conference call, Pfizer noted that it exceeded its cost-saving targets for 2025 and reaffirmed plans to deliver $7.2 billion in cumulative cost reductions by 2027, with the majority of savings expected to be realized in 2026.
Apart from sales, Pfizer reiterated the rest of its 2025 guidance. The company expects to close this year with adjusted EPS between $3.00 and $3.15. Adjusted R&D and SI&A expenses are expected to be in the ranges of $10.0-$11.0 billion and $13.1-$14.1 billion, respectively. The adjusted effective tax rate is expected to be approximately 11% in 2025.
Pfizer’s Growth Visibility Remains Limited Until Late Decade
Looking beyond 2026, Pfizer does not expect a return to robust growth until toward the end of this decade. On the COVID-19 front, the company is targeting total COVID-19 product sales of about $6.5 billion in 2025, but expects this figure to decline by roughly $1.5 billion in 2026. During the conference call, management noted that sales of antiviral Paxlovid are expected to fall more sharply than those of its COVID-19 vaccine.
At the same time, Pfizer faces an escalating patent cliff. While the company expects to bear a $1.5 billion hit from LOEs next year, revenue losses are projected to exceed $3 billion in 2027 and more than $6 billion in 2028.
Excluding COVID-19 products and LOE-impacted drugs, Pfizer is still targeting about 4% year-over-year operational revenue growth. However, management acknowledged that new launches and pipeline contributions will not fully offset these pressures in the near term, delaying a meaningful growth inflection until 2029.
PFE’s Big Bets, Long Timelines Keep Investors Wary
This guidance outlook has raised concerns among investors, who have questioned Pfizer’s investment choices over the past few years, ranging from the $43 billion Seagen acquisition in 2023 to the recent $10 billion buyout of Metsera, which was completed last month.
Pfizer has currently sharpened its strategic focus on two key growth pillars — obesity and oncology. Through the Metsera acquisition, Pfizer is building an early-stage obesity pipeline aimed at eventually competing with market leaders Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) . However, since the Metsera candidates are still in early- to mid-stage development, any meaningful revenue contribution from obesity is unlikely over the next few years.
On the oncology front, Pfizer is prioritizing development of its recently licensed PD-1×VEGF bispecific antibody from China-based 3SBio, positioning it as a potential next-generation immuno-oncology therapy. However, competition in this space is intensifying. Summit Therapeutics (SMMT - Free Report) is advancing its PD-1/VEGF candidate, ivonescimab, in partnership with Akeso, while BioNTech and Bristol Myers Squibb are jointly developing a similar bispecific therapy called BNT327.
PFE’s Price Performance, Valuation and Estimates
Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.19 times forward earnings, lower than 17.18 for the industry and the stock’s 5-year mean of 10.41.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have declined over the past 30 days.
Image: Bigstock
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
Key Takeaways
Shares of Pfizer (PFE - Free Report) dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026, which fell short of investor expectations. The company is expected to have a soft financial performance over the next three years, owing to waning demand for COVID-19 products and a rising loss of exclusivity (LOE) across its portfolio.
Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, which includes $5 billion from the sales of its COVID-19 products. While this outlook is in line with the Zacks Consensus Estimate of $61.83 billion, it implies modest growth compared with the company’s revised 2025 revenue expectation of around $62 billion (previous guidance: $61-$64 billion).
The company also issued guidance for adjusted EPS for 2026, which stood at $2.80-$3.00. This guidance, however, fell short of the Zacks Consensus Estimate of $3.08 per share. Adjusted R&D expenses are expected to be in the range of $10.5 to $11.5 billion in 2026, while adjusted SI&A spending is targeted between $12.5 billion and $13.5 billion. The adjusted effective tax rate is expected to be approximately 15% in 2026.
During the conference call, Pfizer noted that it exceeded its cost-saving targets for 2025 and reaffirmed plans to deliver $7.2 billion in cumulative cost reductions by 2027, with the majority of savings expected to be realized in 2026.
Apart from sales, Pfizer reiterated the rest of its 2025 guidance. The company expects to close this year with adjusted EPS between $3.00 and $3.15. Adjusted R&D and SI&A expenses are expected to be in the ranges of $10.0-$11.0 billion and $13.1-$14.1 billion, respectively. The adjusted effective tax rate is expected to be approximately 11% in 2025.
Pfizer’s Growth Visibility Remains Limited Until Late Decade
Looking beyond 2026, Pfizer does not expect a return to robust growth until toward the end of this decade. On the COVID-19 front, the company is targeting total COVID-19 product sales of about $6.5 billion in 2025, but expects this figure to decline by roughly $1.5 billion in 2026. During the conference call, management noted that sales of antiviral Paxlovid are expected to fall more sharply than those of its COVID-19 vaccine.
At the same time, Pfizer faces an escalating patent cliff. While the company expects to bear a $1.5 billion hit from LOEs next year, revenue losses are projected to exceed $3 billion in 2027 and more than $6 billion in 2028.
Excluding COVID-19 products and LOE-impacted drugs, Pfizer is still targeting about 4% year-over-year operational revenue growth. However, management acknowledged that new launches and pipeline contributions will not fully offset these pressures in the near term, delaying a meaningful growth inflection until 2029.
PFE’s Big Bets, Long Timelines Keep Investors Wary
This guidance outlook has raised concerns among investors, who have questioned Pfizer’s investment choices over the past few years, ranging from the $43 billion Seagen acquisition in 2023 to the recent $10 billion buyout of Metsera, which was completed last month.
Pfizer has currently sharpened its strategic focus on two key growth pillars — obesity and oncology. Through the Metsera acquisition, Pfizer is building an early-stage obesity pipeline aimed at eventually competing with market leaders Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) . However, since the Metsera candidates are still in early- to mid-stage development, any meaningful revenue contribution from obesity is unlikely over the next few years.
On the oncology front, Pfizer is prioritizing development of its recently licensed PD-1×VEGF bispecific antibody from China-based 3SBio, positioning it as a potential next-generation immuno-oncology therapy. However, competition in this space is intensifying. Summit Therapeutics (SMMT - Free Report) is advancing its PD-1/VEGF candidate, ivonescimab, in partnership with Akeso, while BioNTech and Bristol Myers Squibb are jointly developing a similar bispecific therapy called BNT327.
PFE’s Price Performance, Valuation and Estimates
Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.19 times forward earnings, lower than 17.18 for the industry and the stock’s 5-year mean of 10.41.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have declined over the past 30 days.
Image Source: Zacks Investment Research
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.